ELECT: A Phase 3 Study of Efficacy and Safety of Lanreotide Autogel (LAN) Treatment for Carcinoid Syndrome (CS) in Patients (Pts) with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)

#980

Introduction: Somatostatin analogs (SSAs) are the mainstay treatment

Aim(s): ELECT evaluated rescue therapy use as a measure for LAN control of CS symptoms.

Materials and methods: Eligible pts had histologically-confirmed NET and a history of CS, and were SSA naïve or responsive to octreotide LAR ≤30mg/4wks or short-acting SC ≤600μg/day. Design: a 16wk randomized double-blind phase (LAN 120mg [n=59] v. placebo [n=56] every 4wks), and a 32wk open-label LAN extension. Pts had access to octreotide SC as rescue for breakthrough symptoms. Primary endpoint: % of days rescue used during double-blind phase. Study was designed to have 90% power to detect a 30% treatment difference. Double-blind phase results only are presented.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author:

Authors: Gomez-Panzani E, Vinik A, Wolin E, Audry H,

Keywords: symptom control,

To read the full abstract, please log into your ENETS Member account.